Em Ribeirão Preto, pesquisadores da USP iniciaram um estudo que convida quinze mil pessoas a revelar, por meio de seu próprio DNA, o quanto a herança biológica as aproxima ou as afasta do câncer. A iniciativa, integrada ao Programa Nacional de Oncologia, não busca prever destinos individuais, mas construir uma linguagem genética capaz de orientar o sistema de saúde a agir com mais precisão e menos desperdício. É uma aposta antiga da medicina — conhecer para prevenir — agora traduzida em escala e algoritmos.
TNH1
· Apr 10, 2022
· health
· 1 min de lectura
High
Verificación: Verificado
USP launches genetic study to identify cancer risk in 15,000 residents
◉
Health & Medicine
2746 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Cobertura Relacionada
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Brazil's USP launches genetic study of 15,000 residents to develop polygenic cancer risk scores, advancing personalized medicine and healthcare resource allocation in Latin America.
Escalation Risk
low
Confidence
MED
Brazil
Latin America
Global genomics research community
Brazil strengthens its position in precision medicine and genomic research, reducing dependence on foreign health technologies. Participation in international Pronon program enhances Brazil's soft power in healthcare innovation and positions it as a regional leader in genetic research capabilities.
Similar to South Korea and Singapore's investments in genomic research during the 2000s-2010s to establish biotech leadership and reduce healthcare costs through preventive medicine strategies.
Lente Económico
📈
USP's genetic study of 15,000 residents using polygenic scoring aims to optimize cancer prevention resource allocation and enable targeted preventive healthcare, with potential applications to other diseases.
Market Signal
bullish
Confidence
HIGH
Healthcare and pharmaceuticals
Biotechnology and genetic research
Public health administration
Insurance and risk assessment
Medical diagnostics
Consumers may benefit from more personalized, targeted preventive care based on individual genetic risk profiles, potentially reducing unnecessary screenings for low-risk individuals while improving early intervention for high-risk groups. This could lower out-of-pocket healthcare costs for some households.
Government health agencies may restructure preventive care budgets and screening protocols based on polygenic risk stratification. This could inform public health policy on resource allocation, insurance coverage decisions, and preventive medicine standards. Potential regulatory frameworks needed for genetic data privacy and ethical use of polygenic scores in healthcare decisions.